Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139971

Published: 2020

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Blood (2019) 134 (Supplement_1): 2618.

https://doi.org/10.1182/blood-2019-130642

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

Pierre Bories, MD, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2018-99-117219

Published: 2018

Journal Articles

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Emilie Berard, MD, Noemie Gadaud, Audrey Sarry, Francoise Huguet, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2018) 132 (Supplement 1): 2802.

https://doi.org/10.1182/blood-2018-99-113109

Published: 2018

Journal Articles

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Edmond Chiche, Sarah Bonnet, Sarah Bertoli, MD PhD, Andrew T Kuykendall, MD, Lauris Gastaud, Pascal Boulay, Veronique De Mas, Eric Delabesse, MD PhD, Alice Marceau-Renaut, Claude Preudhomme, Anne Murati, David A Sallman, MD, S. Dominique Raynaud, MD, Christian Recher, MD PhD, Norbert Vey, MD PhD, Thomas Cluzeau, MD PhD

Blood (2018) 132 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2018-99-114428

Published: 2018

Journal Articles

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Pierre Bories, MD, Naïs Prade, Bastien Cabarrou, Stéphanie Lagarde, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 1467.

https://doi.org/10.1182/blood-2018-99-117336

Published: 2018

Journal Articles

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Francoise Huguet, MD, Muriel Picard, MD, Francois Vergez, DVM, PhD, Eric Delabesse, MD PhD, Audrey Sarry, Emilie Berard, MD, Christian Recher, MD PhD

Blood (2017) 130 (Supplement 1): 3903.

https://doi.org/10.1182/blood.V130.Suppl_1.3903.3903

Published: 2017

Journal Articles

Platelet Transfusion Refractoriness Following Induction Chemotherapy in Acute Myeloid Leukemia

Thibault Comont, Suzanne Tavitian, MD, Laurent Bardiaux, Marylise Fort, Benedicte Debiol, Daniele Morere, Françoise Huguet, MD, Christian Récher, MD PhD, Sarah Bertoli, MD PhD

Blood (2016) 128 (22): 3987.

https://doi.org/10.1182/blood.V128.22.3987.3987

Published: 2016

Journal Articles

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Sarah Bertoli, MD PhD, Noemie Gadaud, Suzanne Tavitian, MD, Audrey Sarry, Emilie Bérard, MD PhD, Françoise Huguet, MD, Christian Recher, MD PhD

Blood (2016) 128 (22): 3991.

https://doi.org/10.1182/blood.V128.22.3991.3991

Published: 2016

Journal Articles

Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014

Sarah Bertoli, MD PhD, Emilie Bérard, MD PhD, Suzanne Tavitian, MD, Anne Huynh, MD, Cecile Borel, MD, Sarah Guenounou, Isabelle Luquet, MD, Eric Delabesse, PharmD, PhD, Audrey Sarry, Guy Laurent, MD PhD, Michel Attal, Françoise Huguet, MD, Christian Récher, MD PhD

Blood (2016) 128 (22): 3996.

https://doi.org/10.1182/blood.V128.22.3996.3996

Published: 2016

Journal Articles

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Eric Delabesse, PharmD, PhD, Audrey Sarry, Françoise Huguet, MD, Christian Récher, MD PhD

Blood (2016) 128 (22): 1718.

https://doi.org/10.1182/blood.V128.22.1718.1718

Published: 2016

Journal Articles

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Christian Récher, MD PhD, Sarah Bertoli, MD PhD, Muriel Picard, MD, Emilie Bérard, MD PhD, Clément Larrue, PhD, Suzanne Tavitian, MD, Francois Vergez, DVM, PhD, Edwige Yon, Jean Ruiz, MD, Eric Delabesse, PharmD, PhD, Isabelle Luquet, MD, Laetitia Linares, PhD, Martin Carroll, MD, Audrey Sarry, Françoise Huguet, MD, Jean-Emmanuel Sarry, PhD

Blood (2016) 128 (22): 1636.

https://doi.org/10.1182/blood.V128.22.1636.1636

Published: 2016

Journal Articles

Impact of Non Professional Physicians' Characteristics on Medical Decision Making in Older Patients with Acute Myeloid Leukemia

Pierre Bories, MD, Sébastien Lamy, PhD, Celestine Simand, Sarah Bertoli, MD PhD, Sandra Malak, MD, Luc Mathieu Fornecker, MD PhD, Stephane Moreau, MD, Christian Recher, MD PhD, Antoine Nebout, PhD

Blood (2016) 128 (22): 3576.

https://doi.org/10.1182/blood.V128.22.3576.3576

Published: 2016

Journal Articles

Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML

Francois Vergez, DVM, PhD, Sarah Bertoli, MD PhD, Marina Bousquet, PhD, Marie-Laure Nicolau-Travers, Michael Peres, PharmD, Estelle Saland, Françoise Huguet, MD, Isabelle Luquet, MD, Veronique Mansat-de Mas, PharmD, PhD, Cecile Demur, MD, Eric Delabesse, MD PhD, Gwenn Danet-Desnoyers, PhD, Jean-Emmanuel Sarry, PhD, Christian Récher, MDPhD

Blood (2015) 126 (23): 90.

https://doi.org/10.1182/blood.V126.23.90.90

Published: 2015

NARROW

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Platelet Transfusion Refractoriness Following Induction Chemotherapy in Acute Myeloid Leukemia

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Impact of Non Professional Physicians' Characteristics on Medical Decision Making in Older Patients with Acute Myeloid Leukemia

Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only